Virtual Screening in Hepatitis B Virus Drug Discovery: Current Stateof- the-Art and Future Perspectives - Archive ouverte HAL Access content directly
Journal Articles Current Medicinal Chemistry Year : 2018

Virtual Screening in Hepatitis B Virus Drug Discovery: Current Stateof- the-Art and Future Perspectives

(1, 2) , (3) , (1) , (4) , (2) , (2)
1
2
3
4

Abstract

Hepatitis B Virus (HBV) is a major global health burden. Interferon alpha and nucleos(t)ide analogues are currently the standard-of-care for chronic HBV infection. However, these antiviral agents have limited efficacy and do not result in a sustained virological response in the majority of infected patients. Virtual Screening (VS) strategies have now a strong impact on drug discovery, the strength of this research field has been corroborated by recent contributions in the development of novel drug candidates which are in clinical trials or which are already available in the clinics. In this context, different VS strategies have been applied to HBV in order to discover novel inhibitors. In this review, we summarize the VS efforts to identify and design novel HBV interventions. We believe that the combination of in silico and in vitro tools can lead to faster validation of novel drug targets which could accelerate the HBV drug discovery and development efforts.
Fichier principal
Vignette du fichier
20170706_VS_Review_AB3b_SE2_MW_SE3-acc.pdf (240.78 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

pasteur-02528562 , version 1 (01-04-2020)

Identifiers

Cite

Mohcine Elmessaoudi-Idrissi, Arnaud Blondel, Anass Kettani, Marc P Windisch, Soumaya Benjelloun, et al.. Virtual Screening in Hepatitis B Virus Drug Discovery: Current Stateof- the-Art and Future Perspectives. Current Medicinal Chemistry, 2018, 25 (23), pp.2709-2721. ⟨10.2174/0929867325666180221141451⟩. ⟨pasteur-02528562⟩
208 View
537 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More